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Venous thrombo-embolism in people with idiopathic pulmonary fibrosis: a population based study 
Introduction: 
Laboratory studies and animal models have suggested that the activation of the clotting cascade 
may be important in the pathogenesis of IPF.1-3 Epidemiological studies have also suggested a strong 
association between idiopathic pulmonary fibrosis (IPF) and venous thrombo-embolism (VTE).4-6 We 
estimated the incidence of pulmonary embolus (PE) and deep vein thrombosis (DVT) in people with 
IPF and the general population and compared the prevalence of warfarin prescription. 
Methods: 
We used data from The Health Improvement Network (THIN), a UK longitudinal database of 
electronic primary care records containing information recorded in routine clinical care, from face to 
face consultations, and following communication from secondary care. 7 Medical and diagnostic data 
are entered using medical Read codes, a comprehensive list of medical terms for signs, symptoms, 
diagnoses, procedures and investigations. We used the Read codes H563.00 (idiopathic fibrosing 
alveolitis), H563.11 (Hamman-Rich Syndrome), H563.12 (cryptogenic fibrosing alveolitis), H563100 
(diffuse pulmonary fibrosis) and H563z00 (idiopathic fibrosing alveolitis NOS) to identify incident 
cases of Idiopathic Pulmonary Fibrosis Clinical Syndrome (IPF-CS). 
 Cases were included if they were first diagnosed after January 1st 2000 and at least 12 months after 
registration. We excluded people under 40 years at diagnosis, as well as those with co-existing 
connective tissue disease, extrinsic allergic alveolitis, sarcoidosis, pneumoconiosis and asbestosis 
because it is not clear in this subset which diagnoses were correct. For each incident case of IPF-CS, 
we randomly selected up to four general population controls, matched on age, gender and general 
practice. Each case was assigned an index date which corresponded to their first diagnosis of IPF-CS; 
matched controls were assigned the same date as their case.  
We identified individuals with a record of PE or DVT after diagnosis of IPF-CS, excluding those who 
had a PE or DVT prior to the index date. Cox regression was used to estimate incidence rate ratios of 
PE and DVT in people with IPF-CS compared to controls, adjusting for the matching variables, 
smoking and warfarin prescription. We also compared the prevalence of warfarin prescription 
between cases and controls prior to the index date using conditional logistic regression. Proportional 
hazards assumption was confirmed graphically. Likelihood ratio tests were used for all hypothesis 
testing. Statistical analyses were conducted using Stata version 12 (Texas). 
Results:  
We identified 3211 incident cases of IPF-CS and 12,307 matched controls. The cases were mainly 
male (63.9%) and mean age at diagnosis was 75.7 years (standard deviation [SD]: 9.8). Median follow 
up after the index date was 1.7 years (Interquartile Range [IQR] 0.6 to 3.6) in cases and 3.3 years 
(IQR 1.5 to 5.8) for controls. During this time, 2.4% of cases and 0.6% of controls had a recorded PE 
and 1.1% of cases and 0.9% of controls had a diagnosis of DVT. Cases were more likely to have been 
prescribed warfarin (Odds Ratio [OR] 1.52, 95% Confidence Interval [CI] 1.34 to 1.73; p<0.001) prior 
to the index date. After adjusting for matching factors, smoking, and warfarin prescription, the rates 
of PE and DVT were six and two times higher respectively in people with IPF compared to controls 
(see Table 1). There was no evidence that the proportional hazards assumptions were not met. 
Conclusion: 
In this large population based study, we found that people with IPF have higher incidence rates of PE 
and DVT and are more likely to be prescribed warfarin compared to the general population. Possible 
explanations for our finding include a) IPF increasing the risk of VTE or b) a prothombotic state 
leading to the development of IPF and VTE. This study supports the hypothesis that activation of the 
coagulation cascade may be involved in the pathogenesis of IPF.2,8 
 
 
 
 
 
Table 1: Incidence rates and rate ratios for pulmonary embolus and deep vein thrombosis 
Outcome Number 
of 
events 
in cases 
Person-
years 
Crude 
rate in 
cases 
(per 
1000 
pyrs)  
(95% CI) 
Number 
of 
events 
in 
controls 
Person-
years 
Crude rate 
in controls 
(per 1000 
pyrs)  (95% 
CI) 
Rate 
ratio* 
(95% 
CI) 
p value 
Pulmonary 
embolus 
72 7.8 9.3 (7.4-
11.7) 
74 48.4 1.53 (1.2-
1.9) 
6.42 
(4.30- 
9.57) 
<0.001 
Deep Vein 
Thrombosis 
33 7.7 4.3 (3.0-
6.0) 
106 48.1 2.2 (1.8-
2.7) 
2.11 
(1.37-
3.27) 
<0.001 
*Rate ratios stratified for matching variables, smoking habit, and warfarin prescription 
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